SCHEMBL22119481

SCHEMBL22119481

COC(=O)c1cc(NCc2cc(OC)cc(OC)c2)nc(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
AURKA O14965 1/20 0.38
RPS6KB1 P23443 1/20 0.38
AURKB Q96GD4 1/20 0.38
IDH1 O75874 1/20 0.38
SYK P43405 1/20 0.37
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
NQO2 P16083 1/20 0.36
TACR1 P25103 1/20 0.36
DHFR P00374 1/20 0.36
MAOB P27338 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
NPY1R P25929 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3716917 0.83 PIK3CA (0.52) IDH1SYKPIK3CAPIK3CBALDH1A1
SCHEMBL17149371 0.80 TSHR (0.49) MEN1KMT2AALDH1A1CYP1A2CYP2C19
SCHEMBL4504724 0.79 ABL1 (0.52) KMT2ACYP1A2CYP2C19SMN1; SMN2
SCHEMBL19072400 0.77 KMT2A (0.45) MEN1KMT2AIDH1SYKNQO2
SCHEMBL3712550 0.76 HCAR3 (0.42) IDH1SYKNQO2ALDH1A1
SCHEMBL22148690 0.75 KCNQ3 (0.41) PIK3CAPIK3CBMAOB
SCHEMBL25389725 0.75 ESR1 (0.46) IDH1SYKNQO2ALDH1A1
SCHEMBL512745 0.74 NQO2 (0.44) SYKNQO2ALDH1A1
SCHEMBL20814215 0.74 MAPT (0.47) HIF1APIK3CADHFRALDH1A1CYP1A2
SCHEMBL27798554 0.74 KMT2A (0.48) KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098029-A1 KIF18A INHIBITORS AMGEN INC. (US) 2026-04-09 US disclosed
US-12509442-B2 KIF18A inhibitors AMGEN INC. (US) 2025-12-30 US disclosed
US-20240317715-A1 KIF18A INHIBITORS AMGEN INC. (US) 2024-09-26 US disclosed
US-12054476-B2 KIF18A inhibitors AMGEN INC. (US) 2024-08-06 US disclosed
US-20220106293-A1 KIF18A INHIBITORS AMGEN INC. (US) 2022-04-07 US disclosed
US-11236069-B2 KIF18A inhibitors AMGEN INC. (US) 2022-02-01 US disclosed
US-11236069-B2 KIF18A inhibitors AMGEN INC. (US) 2022-02-01 US disclosed
EP-3897852-A1 KIF18A INHIBITORS Amgen Inc. (US) 2021-10-27 EP disclosed
CN-113226473-A KIF18A inhibitors 美国安进公司 2021-08-06 CN disclosed
US-20200239441-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-07-30 US disclosed
US-20200239441-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-07-30 US disclosed
WO-2020132648-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-06-25 WO disclosed
WO-2020132648-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509442-B2 KIF18A inhibitors KIF18A, KIF18B, KIFC1 HIF1A 3338/4885MEN1 4116/4885KMT2A 379/4885
US-20240317715-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 HIF1A 1950/4885MEN1 2120/4885KMT2A 381/4885
US-20220106293-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 HIF1A 1950/4885MEN1 2120/4885KMT2A 381/4885
US-20200239441-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 HIF1A 1950/4885MEN1 2120/4885KMT2A 381/4885
US-12054476-B2 KIF18A inhibitors KIF18A, KIF18B, KIF15 HIF1A 1950/4885MEN1 2120/4885KMT2A 381/4885
US-20260098029-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIFC1 HIF1A 3282/4885MEN1 4094/4885KMT2A 383/4885
US-11236069-B2 KIF18A inhibitors KIF18A, KIF18B, KIF15 HIF1A 1950/4885MEN1 2120/4885KMT2A 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.